Gufic Biosciences Limited (BOM:509079)
417.65
-3.55 (-0.84%)
At close: Aug 17, 2026
Gufic Biosciences Revenue
Gufic Biosciences had revenue of 2.61B INR in the quarter ending June 30, 2026, with 16.58% growth. This brings the company's revenue in the last twelve months to 9.81B, up 16.70% year-over-year. In the fiscal year ending March 31, 2026, Gufic Biosciences had annual revenue of 9.44B with 15.15% growth.
Revenue (ttm)
9.81B
Revenue Growth
+16.70%
P/S Ratio
4.31
Revenue / Employee
6.11M
Employees
1,484
Market Cap
42.24B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 9.44B | 1.24B | 15.15% |
| Mar 31, 2025 | 8.20B | 131.40M | 1.63% |
| Mar 31, 2024 | 8.07B | 1.16B | 16.80% |
| Mar 31, 2023 | 6.91B | -885.35M | -11.36% |
| Mar 31, 2022 | 7.79B | 2.91B | 59.76% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Unichem Laboratories | 23.17B |
| FDC Limited | 21.90B |
| Morepen Laboratories | 19.51B |
| Sanofi India | 18.05B |
| Hikal | 17.35B |
| Bliss GVS Pharma | 10.05B |
| Venus Remedies | 8.11B |
| Fredun Pharmaceuticals | 7.44B |
Gufic Biosciences News
- 7 hours ago - Gufic Biosciences Quarterly report: Q1 2027 - Filings
- 2 months ago - Gufic Biosciences Transcript: Q4 25/26 - Transcripts
- 2 months ago - Gufic Biosciences Quarterly report: Q4 2026 - Filings
- 2 months ago - Gufic Biosciences Slides: Q4 2026 - Filings
- 2 months ago - Gufic Biosciences Annual report: Q4 2026 - Filings
- 6 months ago - Gufic Biosciences Transcript: Q3 25/26 - Transcripts
- 6 months ago - Gufic Biosciences Quarterly report: Q3 2026 - Filings
- 6 months ago - Gufic Biosciences Slides: Q3 2026 - Filings